Download MendeleyDiscovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors.
Calvo, V., Surguladze, D., Li, A.H., Surman, M.D., Malibhatla, S., Bandaru, M., Jonnalagadda, S.K., Adarasandi, R., Velmala, M., Singireddi, D.R.P., Velpuri, M., Nareddy, B.R., Sastry, V., Mandati, C., Guguloth, R., Siddiqui, S., Patil, B.S., Chad, E., Wolfley, J., Gasparek, J., Feldman, K., Betzenhauser, M., Wiens, B., Koszelak-Rosenblum, M., Zhu, G., Du, H., Rigby, A.C., Mulvihill, M.J.(2021) Bioorg Med Chem Lett 43: 128058-128058
- PubMed: 33895276
- DOI: https://doi.org/10.1016/j.bmcl.2021.128058
- Primary Citation of Related Structures:
7MF0 - PubMed Abstract:
The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of the three endoplasmic reticulum (ER) transmembrane sensors of the unfolded protein response (UPR) that regulates protein synthesis, alleviates cellular ER stress and has been implicated in tumorigenesis and prolonged cancer cell survival. In this study, we report a series of 2-amino-3-amido-5-aryl-pyridines that we have identified as potent, selective, and orally bioavailable PERK inhibitors. Amongst the series studied herein, compound (28) a (R)-2-Amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-ethylphenyl)-N-isopropylnicotinamide has demonstrated potent biochemical and cellular activity, robust pharmacokinetics and 70% oral bioavailability in mice. Given these data, this compound (28) was studied in the 786-O renal cell carcinoma xenograft model. We observed dose-dependent, statistically significant tumor growth inhibition, supporting the use of this tool compound in additional mechanistic studies.
Organizational Affiliation:
HiberCell Inc. 619 West 54th Street, New York, NY 10019, USA.
